Cirrhosis/Liver Failure News

In today’s researcher blog from DDW, Jasmohan S. Bajaj, MBBS, MD, MS, offers insight into his new smartphone application that can quickly identify patients at risk for hepatic encephalopathy.

Liver surface nodularity measurements from routine computed tomography images in adult patients with cirrhosis accurately predicted liver decompensation and overall survival, according to data presented at the 2015 American Roentgen Ray Society Annual Meeting.

VIENNA — A majority of patients hospitalized with cirrhosis were readmitted to the hospital due to infection and other liver-related complications within 3 months of being discharged, according to a poster presented at the 2015 International Liver Congress.

Treatment-naive and experienced patients with chronic hepatitis C virus genotype 1 infection and cirrhosis achieved a sustained virologic response at 12 weeks while on a fixed-dose regimen of daclatasvir, asunaprevir and beclabuvir, according to newly published data in JAMA.

The mortality rate of patients hospitalized for cirrhosis has decreased more than 40% between 2002 and 2010, despite an increase in hospital admissions, according to newly published data.

VIENNA — Antonio Riva, PhD, from the Institute of Hepatology, Foundation for Liver Research, London, United Kingdom, discusses his study on assessing the role of Mucosal-associated invariant T-cells, or MAIT cells, in alcoholic liver disease at the 2015 International Liver Congress.

VIENNA — A regimen containing Sovaldi and daclatasvir was associated with favorable 12-week sustained virologic response rates in a cohort of patients with advanced cirrhosis, according to data presented at the 2015 International Liver Congress.

VIENNA — A new algorithm accurately predicted hepatocellular carcinoma among a cohort of patients with cirrhosis, according to a study presented at the 2015 International Liver Congress.

VIENNA — Cardiovascular risks increased with rising severity of non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and cirrhosis, according to a study presented at the 2015 International Liver Congress.

VIENNA — A novel combination regimen of grazoprevir and elbasvir was associated with favorable responses in a cohort of patients with advanced cirrhosis, according to findings presented at the 2015 International Liver Congress.